Literature DB >> 19651211

Mouse AMACO, a kidney and skin basement membrane associated molecule that mediates RGD-dependent cell attachment.

Jan M Gebauer1, Douglas R Keene, Bjorn R Olsen, Lydia M Sorokin, Mats Paulsson, Raimund Wagener.   

Abstract

The VWA domain-containing extracellular matrix protein AMACO has not been extensively characterized and its function remains unknown. It has been proposed as a potential cancer marker and carries a rare O-glucosylation and O-fucosylation on its first EGF-like domain. AMACO is a basement membrane associated protein, however its exact localization has not been determined. Here we show by immunogold electron microscopy of mouse kidney and skin that AMACO does not occur within the basement membrane but rather subjacent to the basement membrane at its stromal surface. In skin, AMACO often colocalizes with triple-helical domains of collagen VII containing anchoring fibrils as they emerge from the basal lamina. However, the immunogold patterns for AMACO and the C-terminal end of collagen VII show discrete differences, indicating that AMACO and collagen VII do not colocalize at anchoring plaques. In contrast, the localization pattern of AMACO partially overlaps with that for collagen XVIII. In addition, mouse AMACO was shown to support beta1 integrin-mediated adhesion of a keratinocyte-like cell line, HaCaT, and a fibroblast cell line, Wi26, in an RGD-dependent manner, most likely using an RGD-motif near the C-terminus of AMACO. However, the loss of cell adhesion to the C-terminal part of the human AMACO, due to the unique absence of an RGD sequence in the human protein, suggests that cell adhesion is not AMACO's major function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651211     DOI: 10.1016/j.matbio.2009.07.006

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  7 in total

1.  AMACO is a component of the basement membrane-associated Fraser complex.

Authors:  Rebecca J Richardson; Jan M Gebauer; Jin-Li Zhang; Birgit Kobbe; Douglas R Keene; Kristina Røkenes Karlsen; Stefânia Richetti; Alexander P Wohl; Gerhard Sengle; Wolfram F Neiss; Mats Paulsson; Matthias Hammerschmidt; Raimund Wagener
Journal:  J Invest Dermatol       Date:  2013-11-14       Impact factor: 8.551

2.  A homozygous missense variant in VWA2, encoding an interactor of the Fraser-complex, in a patient with vesicoureteral reflux.

Authors:  Amelie T van der Ven; Birgit Kobbe; Stefan Kohl; Shirlee Shril; Hans-Martin Pogoda; Thomas Imhof; Hadas Ityel; Asaf Vivante; Jing Chen; Daw-Yang Hwang; Dervla M Connaughton; Nina Mann; Eugen Widmeier; Mary Taglienti; Johanna Magdalena Schmidt; Makiko Nakayama; Prabha Senguttuvan; Selvin Kumar; Velibor Tasic; Elijah O Kehinde; Shrikant M Mane; Richard P Lifton; Neveen Soliman; Weining Lu; Stuart B Bauer; Matthias Hammerschmidt; Raimund Wagener; Friedhelm Hildebrandt
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

3.  Von Willebrand Factor Type A domain of hCLCA1 is sufficient for U-937 macrophage activation.

Authors:  Brandon A Keith; John C H Ching; Matthew E Loewen
Journal:  Biochem Biophys Rep       Date:  2019-03-28

4.  Structural and biophysical characterization of the type VII collagen vWFA2 subdomain leads to identification of two binding sites.

Authors:  Jan M Gebauer; Florian Flachsenberg; Cordula Windler; Barbara Richer; Ulrich Baumann; Karsten Seeger
Journal:  FEBS Open Bio       Date:  2020-03-14       Impact factor: 2.693

5.  A new component of the Fraser complex.

Authors:  Sho Hiroyasu; Jonathan C R Jones
Journal:  J Invest Dermatol       Date:  2014-05       Impact factor: 8.551

6.  Ablation of coactivator Med1 switches the cell fate of dental epithelia to that generating hair.

Authors:  Keigo Yoshizaki; Lizhi Hu; Thai Nguyen; Kiyoshi Sakai; Bing He; Chak Fong; Yoshihiko Yamada; Daniel D Bikle; Yuko Oda
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

7.  Epigenetic and transcriptional dysregulation of VWA2 associated with a MYC-driven oncogenic program in colorectal cancer.

Authors:  Beatriz González; Ferran Fece de la Cruz; Johanna Kristina Samuelsson; Andreu Alibés; Sergio Alonso
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.